Surgical marker pen linked to DLK outbreak

Article

Refractive surgeons should be aware of the possibility that a surgical marker pen (Codman; Johnson & Johnson) could be a cause of diffuse lamellar keratitis (DLK) after LASIK, said Wei-Han Chua, MD.

Refractive surgeons should be aware of the possibility that a surgical marker pen (Codman; Johnson & Johnson) could be a cause of diffuse lamellar keratitis (DLK) after LASIK, said Wei-Han Chua, MD.

Dr Chua reported on a cluster of nine cases of DLK that occurred at the Singapore National Eye Centre. All eyes had undergone LASIK or flap relift/repositioning on a single day (July 24, 2007) and DLK of varying grades was noted on the first postoperative day.

To investigate the outbreak, a review was undertaken of all LASIK procedures performed over the four-day period from July 23 to 26, 2007. DLK occurred in nine of 12 eyes that had surgery on July 24th with use of the surgical marker pen and in none of 113 eyes operated on during the other three days when a surgical marker pen from another manufacturer was used to ink the corneal marker. Dr Chua postulated that one or more of the constituents of the ink in the surgical marker pen in question might have incited the inflammatory response.

"It can be difficult to identify risk factors or causative agents in DLK, even when outbreaks occur. However, because of the use of strict protocols for recording the introduction of all new equipment and consumables used for LASIK procedures, we could determine that the introduction of a new brand of surgical markers was the only change made to the surgical regimen on the day the DLK eyes had their procedures," Dr Chua said.

"To our knowledge, this is the first report of DLK associated with a surgical marker. After we communicated our experience, the manufacturer replied that the surgical marker is intended for use only on the skin and is not meant to be used on the eyes," he concluded.

 

Read

ASCRS 2008 meeting highlights.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.